Horizon
Bookmark
ShareCopied to clipboardHorizon is a company. It is a public company in Dublin, Ireland. It was founded in 2008 and its current CEO is Timothy P. Walbert. It is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Dublin
- country: Ireland
- employees: 2,015 people
- revenues: 3.8B $
- company type: public
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 2008
- CEO: Timothy P. Walbert
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Horizon:
Dataset of stocks from Horizon:
Horizon is one of the companies in Ireland, companies in Pharmaceuticals, companies in Health Care, companies in Dublin and 3,456,808 companies in our database.
Talking Points
- Horizon Therapeutics is a biotechnology company that is driven to deliver breakthrough medicines to patients because we understand the challenges they face.
- At Horizon, we believe science and compassion must work together to transform lives.
- Going to Incredible Lengths | At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most ...
- Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.